Condition: Treatment-Resistant Depression · Sponsor: Centre for Addiction and Mental Health
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychological support in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. The purpose of this study is to determine the role of psilocybin monitors on the effects of psilocybin therapy in adults with treatment resistant depression.
This description comes directly from the study's public registry record.
Emily Gilbert, MSc · 4165358501 · emily.gilbert@camh.ca
Psychedelics Research · psychedelics.research@camh.ca
Always discuss trial participation with your own doctor first.
| Toronto Western Hospital (University Health Network) | Toronto, Ontario, Canada | Not Yet Recruiting |
| Centre for Addiction and Mental Health | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07211438